SEC Form 4 · accession 0000899243-18-006954
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael John Tomsicek
Officer — Chief Financial Officer
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $51.49 | Mar 7, 2018 | A | 25,000 | A | — | Mar 7, 2028 | Common Shares | 25,000 | 25,000 | D |
Explanation of responses
- F1This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments.